Cargando…

LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease

Genetic alterations in the LRRK2 gene, encoding leucine-rich repeat kinase 2, are a common risk factor for Parkinson’s disease. How LRRK2 alterations lead to cell pathology is an area of ongoing investigation, however, multiple lines of evidence suggest a role for LRRK2 in lipid pathways. It is incr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galper, Jasmin, Kim, Woojin S., Dzamko, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687231/ https://www.ncbi.nlm.nih.gov/pubmed/36358947 http://dx.doi.org/10.3390/biom12111597

Ejemplares similares

Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease
por: Galper, Jasmin, et al.
Publicado: (2022)

LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
por: Atashrazm, Farzaneh, et al.
Publicado: (2016)

Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease
por: Galper, Jasmin, et al.
Publicado: (2021)

Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2
por: Deng, Xianming, et al.
Publicado: (2011)

LRRK2 and Proteostasis in Parkinson’s Disease
por: Pérez-Carrión, María Dolores, et al.
Publicado: (2022)

LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease
por: Pang, Shirley Yin-Yu, et al.
Publicado: (2022)

LRRK2 and the Endolysosomal System in Parkinson’s Disease
por: Erb, Madalynn L., et al.
Publicado: (2020)

LRRK2 at the Crossroad of Aging and Parkinson’s Disease
por: Hur, Eun-Mi, et al.
Publicado: (2021)

Pathological Functions of LRRK2 in Parkinson’s Disease
por: Jeong, Ga Ram, et al.
Publicado: (2020)

Live cell in situ lysosomal GCase activity correlates to alpha-synuclein levels in human differentiated neurons with LRRK2 and GBA1 mutations
por: Labrador-Garrido, Adahir, et al.
Publicado: (2023)

The role of the LRRK2 gene in Parkinsonism
por: Li, Jie-Qiong, et al.
Publicado: (2014)

LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
por: Russo, Isabella, et al.
Publicado: (2014)

Roco Proteins and the Parkinson’s Disease-Associated LRRK2
por: Liao, Jingling, et al.
Publicado: (2018)

Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker
por: Perera, G., et al.
Publicado: (2016)

Molecular Pathways Involved in LRRK2-Linked Parkinson’s Disease: A Systematic Review
por: Ravinther, Ailyn Irvita, et al.
Publicado: (2022)

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
por: Nichols, R. Jeremy, et al.
Publicado: (2010)

Models for LRRK2-Linked Parkinsonism
por: Li, Tianxia, et al.
Publicado: (2011)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Parkinson's disease and mitophagy: an emerging role for LRRK2
por: Singh, Francois, et al.
Publicado: (2021)

Parkinson’s disease-implicated kinases in the brain; insights into disease pathogenesis
por: Dzamko, Nicolas, et al.
Publicado: (2014)

LRRK2 and membrane trafficking: nexus of Parkinson’s disease
por: Hur, Eun-Mi, et al.
Publicado: (2019)

Contribution of GTPase activity to LRRK2-associated Parkinson disease
por: Tsika, Elpida, et al.
Publicado: (2013)

LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease
por: Wojewska, Dominika Natalia, et al.
Publicado: (2021)

Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson’s Disease
por: Ito, Genta, et al.
Publicado: (2023)

The role of LRRK2 on PKA-NFκB pathway in microglia cells: implications for Parkinson’s disease
por: Russo, Isabella
Publicado: (2019)

Cytokine activity in Parkinson’s disease
por: Dzamko, Nicolas
Publicado: (2023)

The LRRK2–macroautophagy axis and its relevance to Parkinson's disease
por: Manzoni, Claudia
Publicado: (2017)

LRRK2 and Parkinson's disease: from genetics to targeted therapy
por: Sosero, Yuri L., et al.
Publicado: (2023)

Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients
por: Youssef, Priscilla, et al.
Publicado: (2021)

The Role of LRRK2 in Neurodegeneration of Parkinson Disease
por: Rui, Qin, et al.
Publicado: (2018)

Modeling Parkinson’s disease in LRRK2 rodents
por: Domenicale, Chiara, et al.
Publicado: (2023)

Is Glial Dysfunction the Key Pathogenesis of LRRK2-Linked Parkinson’s Disease?
por: Iseki, Tatou, et al.
Publicado: (2023)

An Update on the Interplay between LRRK2, Rab GTPases and Parkinson’s Disease
por: Komori, Tadayuki, et al.
Publicado: (2023)

Investigating lymphocyte populations in patients with Parkinson’s disease
por: Dzamko, Nicolas
Publicado: (2020)

Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers
por: Zhao, Ye, et al.
Publicado: (2018)

A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease
por: Gómez-Suaga, Patricia, et al.
Publicado: (2012)

Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease
por: Rosenbusch, Katharina E., et al.
Publicado: (2016)

The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling
por: Dzamko, Nicolas, et al.
Publicado: (2012)

Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease?
por: Herrick, Mary K., et al.
Publicado: (2021)

LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease
por: Chang, Eunice Eun Seo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ul1c7mlvitd4ombomtq154tgae